Status:
COMPLETED
Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-80 years
Phase:
PHASE3
Brief Summary
This study was designed to look at effects of salmeterol/fluticasone propionate compared to placebo on airway inflammation in patients with chronic obstructive airways disease
Eligibility Criteria
Inclusion
- Established clinical history of chronic obstructive airways disease.
- Must be current or ex-smokers with a smoking history of at least 10 pack-years (e.g. 20 cigarettes/day for 10 years or 10 cigarettes/day for 20 years).
- Must have reduced lung function, defined as a Forced Expiratory Volume in 1 second (FEV1) of between 40-80% of predicted normal values.
Exclusion
- Diagnosis of any other serious disease and must have a chest X-ray to eliminate a diagnosis other than COPD.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00268177
Start Date
October 1 2002
End Date
December 1 2003
Last Update
September 15 2016
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Aalborg, Denmark, DK-9100
2
GSK Investigational Site
København NV, Denmark, 2400
3
GSK Investigational Site
Tallinn, Estonia, 13419
4
GSK Investigational Site
Tartu, Estonia, 51014